Scarica l'app Stockscreener
140.64
2.60%
3.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$137.08
Aprire:
$138
Volume 24 ore:
1.77M
Relative Volume:
1.21
Capitalizzazione di mercato:
$20.59B
Reddito:
$9.61B
Utile/perdita netta:
$1.62B
Rapporto P/E:
12.70
EPS:
11.07
Flusso di cassa netto:
$1.77B
1 W Prestazione:
+2.41%
1M Prestazione:
-0.24%
6M Prestazione:
-31.79%
1 anno Prestazione:
-36.39%
Intervallo 1D:
$137.56
$141.50
Intervallo di 1 settimana:
$135.02
$141.50
Portata 52W:
$128.51
$238.00
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
140.64 | 20.59B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Allianz Asset Management GmbH Has $81.96 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Biogen Inc. (NASDAQ:BIIB) Stock Position Increased by Meitav Investment House Ltd. - MarketBeat
Ieq Capital LLC Buys 55,514 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Stock Is Mutating Into a Value Play - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by ICICI Prudential Asset Management Co Ltd - MarketBeat
What is Wedbush's Forecast for Biogen Q1 Earnings? - MarketBeat
Alberta Investment Management Corp Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $751,000 Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
New York State Teachers Retirement System Sells 6,673 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Stoke Partner on Zorevunersen in Dravet Syndrome - Contract Pharma
Biogen's (BIIB) "Neutral" Rating Reiterated at Piper Sandler - MarketBeat
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative - Simply Wall St
Kentucky Retirement Systems Insurance Trust Fund Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - News & Insights
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Oppenheimer maintains Biogen Outperform with $255 target - Investing.com
Biogen stock price target cut to $159 by Bernstein SocGen - Investing.com Australia
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Yahoo Finance
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
Bernstein Adjusts Price Target on Biogen to $159 From $160, Keeps Market Perform Rating - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Piper Sandler cuts Biogen price target to $135, keeps neutral rating - Investing.com India
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MarketWatch
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Biogen | Investor Relations
Major Epilepsy Treatment Breakthrough: Biogen Acquires Rights to FDA-Designated Therapy in Massive Deal - StockTitan
Biogen's SWOT analysis: stock faces challenges amid pipeline potential - Investing.com
Rhumbline Advisers Has $41.07 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Banque Pictet & Cie SA Raises Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cantor Fitzgerald Reduces Earnings Estimates for Biogen - MarketBeat
Biogen's (BIIB) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
Morgan Stanley Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Acquires New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
The Goldman Sachs Group Cuts Biogen (NASDAQ:BIIB) Price Target to $245.00 - MarketBeat
Stephens Inc. AR Sells 2,270 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Q1 Earnings Estimate for Biogen Issued By Leerink Partnrs - MarketBeat
19,574 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Strategic Financial Concepts LLC - MarketBeat
Viral Gene Therapy Market May See a Big Move | Biogen, Novartis AG, Gilead Sciences - openPR
Vontobel Holding Ltd. Increases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Reports Q4 and Full-Year 2024 Results: Strong EPS Growth Amid Revenue Challenges - BSA bureau
William Blair Issues Optimistic Estimate for Biogen Earnings - MarketBeat
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.61%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):